Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734531 | 0.82 | IDO1 (0.40) | MAPTGAATSHRMAPK1POLB | |
| SCHEMBL24513009 | 0.80 | PARP10 (0.41) | ALDH1A1SMN1; SMN2POLBBTKSOS1 | |
| SCHEMBL16659206 | 0.79 | SMN1; SMN2 (0.56) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL633116 | 0.78 | ALDH1A1 (0.64) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL16792533 | 0.76 | ALDH1A1 (0.61) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1283223 | 0.76 | ALDH1A1 (0.50) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL30768354 | 0.76 | NR4A1 (0.45) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL24750258 | 0.76 | NR4A1 (0.45) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4096194 | 0.76 | ALDH1A1 (0.71) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL23646714 | 0.75 | KDR (0.43) | CYP3A4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180461-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-11180461-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| EP-2852589-B1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2021-04-28 | — | — | EP | disclosed |
| EP-2852589-B1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY SRL (IT) | 2020-06-04 | — | — | US | disclosed |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY SRL (IT) | 2020-06-04 | — | — | US | disclosed |
| US-10611735-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-07 | — | — | US | disclosed |
| US-10611735-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-07 | — | — | US | disclosed |
| US-20190071405-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2019-03-07 | — | — | US | disclosed |
| US-20190071405-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2019-03-07 | — | — | US | disclosed |
| US-20160318882-A1 | TRIAZOLES AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2016-11-03 | — | — | US | disclosed |
| US-20160318882-A1 | TRIAZOLES AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2016-11-03 | — | — | US | disclosed |
| US-9422252-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-9422252-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-9422252-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| EP-2852589-A1 | TRIAZOLES AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2015-04-01 | — | — | EP | disclosed |
| WO-2013175215-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611735-B2 | Triazoles as Kv3 inhibitors | KCNA3, KCNN3, KCNK3 | ALDH1A1 2268/4885MAPT 2617/4885SMN1; SMN2 3663/4885 |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | ALDH1A1 2268/4885MAPT 2617/4885SMN1; SMN2 3663/4885 |
| US-20190071405-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | ALDH1A1 2268/4885MAPT 2617/4885SMN1; SMN2 3663/4885 |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | ALDH1A1 2268/4885MAPT 2617/4885SMN1; SMN2 3663/4885 |
| US-11180461-B2 | Triazoles as Kv3 inhibitors | KCNA3, KCNN3, KCNK3 | ALDH1A1 2268/4885MAPT 2617/4885SMN1; SMN2 3663/4885 |
| US-20160318882-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | ALDH1A1 2268/4885MAPT 2617/4885SMN1; SMN2 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.